Does the media prefer COGT or IMCR?

In the previous week, Cogent Biosciences had 1 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Immunocore. Cogent Biosciences' average media sentiment score of 0.68 beat Immunocore's score of 0.33 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PTCT or IMCR?

In the previous week, PTC Therapeutics had 5 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for PTC Therapeutics and 1 mentions for Immunocore. PTC Therapeutics' average media sentiment score of 1.44 beat Immunocore's score of 0.33 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMCR or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Immunocore -6.68% -7.07% -2.55% Belite Bio N/A -13.14% -12.88%

Does the media prefer IMCR or BLTE?

In the previous week, Belite Bio had 2 more articles in the media than Immunocore. MarketBeat recorded 3 mentions for Belite Bio and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.33 beat Belite Bio's score of 0.00 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IMCR or LEGN?

In the previous week, Legend Biotech had 11 more articles in the media than Immunocore. MarketBeat recorded 12 mentions for Legend Biotech and 1 mentions for Immunocore. Legend Biotech's average media sentiment score of 0.59 beat Immunocore's score of 0.33 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, IMCR or GRFS?

Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunocore $400.02M 3.52 -$35.51M -$0.55 N/A Grifols $8.51B 0.59 $454.82M $0.19 38.58

Is IMCR or GRFS more profitable?

Grifols has a net margin of 5.54% compared to Immunocore's net margin of -6.68%. Grifols' return on equity of 6.21% beat Immunocore's return on equity. Company Net Margins Return on Equity Return on Assets Immunocore -6.68% -7.07% -2.55% Grifols 5.54% 6.21% 2.39%

Does the media prefer IMCR or GRFS?

In the previous week, Grifols had 1 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for Grifols and 1 mentions for Immunocore. Grifols' average media sentiment score of 1.64 beat Immunocore's score of 0.33 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Immunocore (IMCR) Competitors

$27.79 -0.50 (-1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$28.35 +0.56 (+2.02%)

As of 07:56 PM Eastern

Compare

IMCR vs. COGT, PTCT, BLTE, LEGN, and GRFS

Should you buy Immunocore stock or one of its competitors? MarketBeat compares Immunocore with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunocore include Cogent Biosciences (COGT), PTC Therapeutics (PTCT), Belite Bio (BLTE), Legend Biotech (LEGN), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does Immunocore compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Cogent Biosciences has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Immunocore	-6.68%	-7.07%	-2.55%

Immunocore has higher revenue and earnings than Cogent Biosciences. Immunocore is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Immunocore	$400.02M	3.52	-$35.51M	-$0.55	N/A

84.5% of Immunocore shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cogent Biosciences had 1 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for Cogent Biosciences and 1 mentions for Immunocore. Cogent Biosciences' average media sentiment score of 0.68 beat Immunocore's score of 0.33 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Cogent Biosciences presently has a consensus target price of $43.73, suggesting a potential upside of 40.33%. Immunocore has a consensus target price of $56.71, suggesting a potential upside of 104.08%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Immunocore beats Cogent Biosciences on 9 of the 16 factors compared between the two stocks.

How does Immunocore compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

PTC Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

84.5% of Immunocore shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PTC Therapeutics has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.40	$682.64M	-$2.33	N/A
Immunocore	$400.02M	3.52	-$35.51M	-$0.55	N/A

In the previous week, PTC Therapeutics had 5 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for PTC Therapeutics and 1 mentions for Immunocore. PTC Therapeutics' average media sentiment score of 1.44 beat Immunocore's score of 0.33 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunocore has a net margin of -6.68% compared to PTC Therapeutics' net margin of -22.58%. Immunocore's return on equity of -7.07% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Immunocore	-6.68%	-7.07%	-2.55%

PTC Therapeutics presently has a consensus target price of $89.00, indicating a potential upside of 25.58%. Immunocore has a consensus target price of $56.71, indicating a potential upside of 104.08%. Given Immunocore's higher probable upside, analysts clearly believe Immunocore is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Immunocore beats PTC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Immunocore compare to Belite Bio?

Immunocore (NASDAQ:IMCR) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Belite Bio had 2 more articles in the media than Immunocore. MarketBeat recorded 3 mentions for Belite Bio and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.33 beat Belite Bio's score of 0.00 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunocore has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.52	-$35.51M	-$0.55	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Belite Bio has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Belite Bio	N/A	-13.14%	-12.88%

Immunocore presently has a consensus target price of $56.71, indicating a potential upside of 104.08%. Belite Bio has a consensus target price of $203.00, indicating a potential upside of 45.38%. Given Immunocore's higher possible upside, research analysts plainly believe Immunocore is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Immunocore has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, suggesting that its share price is 224% less volatile than the broader market.

Summary

Immunocore beats Belite Bio on 11 of the 16 factors compared between the two stocks.

How does Immunocore compare to Legend Biotech?

Immunocore (NASDAQ:IMCR) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Immunocore has higher earnings, but lower revenue than Legend Biotech. Immunocore is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.52	-$35.51M	-$0.55	N/A
Legend Biotech	$1.03B	5.69	-$296.80M	-$0.68	N/A

Immunocore has a net margin of -6.68% compared to Legend Biotech's net margin of -21.98%. Immunocore's return on equity of -7.07% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Legend Biotech	-21.98%	-24.92%	-14.87%

Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

84.5% of Immunocore shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immunocore currently has a consensus target price of $56.71, suggesting a potential upside of 104.08%. Legend Biotech has a consensus target price of $60.23, suggesting a potential upside of 91.09%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Legend Biotech had 11 more articles in the media than Immunocore. MarketBeat recorded 12 mentions for Legend Biotech and 1 mentions for Immunocore. Legend Biotech's average media sentiment score of 0.59 beat Immunocore's score of 0.33 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Legend Biotech	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunocore beats Legend Biotech on 10 of the 17 factors compared between the two stocks.

How does Immunocore compare to Grifols?

Immunocore (NASDAQ:IMCR) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Immunocore currently has a consensus target price of $56.71, indicating a potential upside of 104.08%. Grifols has a consensus target price of $10.00, indicating a potential upside of 36.43%. Given Immunocore's stronger consensus rating and higher probable upside, equities research analysts clearly believe Immunocore is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Grifols has a net margin of 5.54% compared to Immunocore's net margin of -6.68%. Grifols' return on equity of 6.21% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Grifols	5.54%	6.21%	2.39%

84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.52	-$35.51M	-$0.55	N/A
Grifols	$8.51B	0.59	$454.82M	$0.19	38.58

In the previous week, Grifols had 1 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for Grifols and 1 mentions for Immunocore. Grifols' average media sentiment score of 1.64 beat Immunocore's score of 0.33 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Grifols has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Summary

Grifols beats Immunocore on 9 of the 17 factors compared between the two stocks.

Get Immunocore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCR vs. The Competition

Export

Metric	Immunocore	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.43B	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-50.53	18.61	23.92	23.74
Price / Sales	3.52	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	3.70	8.04	10.28	6.78
Net Income	-$35.51M	$23.89M	$3.57B	$337.51M
7 Day Performance	-4.60%	-5.97%	-1.43%	-2.72%
1 Month Performance	-6.05%	2.78%	3.27%	1.87%
1 Year Performance	-25.40%	36.26%	23.37%	26.60%

Immunocore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCR Immunocore	2.8144 of 5 stars	$27.79 -1.8%	$56.71 +104.1%	-24.1%	$1.43B	$400.02M	N/A	320
COGT Cogent Biosciences	3.2852 of 5 stars	$33.52 +2.6%	$43.73 +30.5%	+356.2%	$5.73B	N/A	N/A	80	Gap Up
PTCT PTC Therapeutics	3.6367 of 5 stars	$67.46 -2.0%	$88.36 +31.0%	+36.1%	$5.60B	$827.11M	N/A	1,410	News Coverage Positive News
BLTE Belite Bio	2.6069 of 5 stars	$136.79 -0.4%	$203.80 +49.0%	+140.2%	$5.47B	N/A	N/A	10
LEGN Legend Biotech	4.1083 of 5 stars	$29.34 -0.1%	$59.00 +101.1%	-6.8%	$5.43B	$1.03B	N/A	2,965

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCR) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunocore (IMCR) Competitors

IMCR vs. COGT, PTCT, BLTE, LEGN, and GRFS

How does Immunocore compare to Cogent Biosciences?

Summary

How does Immunocore compare to PTC Therapeutics?

Summary

How does Immunocore compare to Belite Bio?

Summary

How does Immunocore compare to Legend Biotech?

Summary

How does Immunocore compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunocore (IMCR) Competitors

IMCR vs. COGT, PTCT, BLTE, LEGN, and GRFS

How does Immunocore compare to Cogent Biosciences?

Is COGT or IMCR more profitable?

Which has stronger valuation and earnings, COGT or IMCR?

Do insiders & institutionals hold more shares of COGT or IMCR?

Does the media prefer COGT or IMCR?

Which has more volatility and risk, COGT or IMCR?

Do analysts prefer COGT or IMCR?

Summary

How does Immunocore compare to PTC Therapeutics?

Which has more risk and volatility, PTCT or IMCR?

Do institutionals & insiders believe in PTCT or IMCR?

Which has higher earnings & valuation, PTCT or IMCR?

Does the media refer more to PTCT or IMCR?

Is PTCT or IMCR more profitable?

Do analysts rate PTCT or IMCR?

Summary

How does Immunocore compare to Belite Bio?

Do institutionals & insiders believe in IMCR or BLTE?

Does the media prefer IMCR or BLTE?

Which has stronger earnings and valuation, IMCR or BLTE?

Is IMCR or BLTE more profitable?

Do analysts rate IMCR or BLTE?

Which has more volatility & risk, IMCR or BLTE?

Summary

How does Immunocore compare to Legend Biotech?

Which has better earnings and valuation, IMCR or LEGN?

Is IMCR or LEGN more profitable?

Which has more volatility and risk, IMCR or LEGN?

Do institutionals and insiders hold more shares of IMCR or LEGN?

Do analysts recommend IMCR or LEGN?

Does the media prefer IMCR or LEGN?

Summary

How does Immunocore compare to Grifols?

Do analysts rate IMCR or GRFS?

Is IMCR or GRFS more profitable?

Do institutionals & insiders believe in IMCR or GRFS?

Which has better earnings and valuation, IMCR or GRFS?

Does the media prefer IMCR or GRFS?

Which has more risk and volatility, IMCR or GRFS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools